Benjamin Solomon

发表

Benjamin Solomon, 1997 .

Evaluation of an artificial intelligence clinical trial matching system in Australian lung cancer patients

Gretchen Purcell Jackson, Benjamin Solomon, Marliese Alexander, 2020, JAMIA open.

Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial.

Tomas Kron, Andrew Wirth, Benjamin Solomon, 2019, The Lancet. Oncology.

Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors

Martin Vingron, Thomas Zander, Yupeng Cun, 2018, Nature Communications.

Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases.

Lucio Crinò, Benjamin Solomon, Patrick Schnell, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothe

Carsten Denkert, Fred Hirsch, Benjamin Solomon, 2017, Advances in anatomic pathology.

A community-based model of rapid autopsy in end-stage cancer patients

Anthony T Papenfuss, Mohammed Madadin, Mark Shackleton, 2016, Nature Biotechnology.

Frequent mutations in chromatin-remodeling genes in pulmonary carcinoids

Martin Vingron, Thomas Zander, Viktor Achter, 2014, Nature Communications.

Rationale for co-targeting IGF-1R and ALK in ALK fusion positive lung cancer

William Pao, Zhongming Zhao, Ronglai Shen, 2014, Nature Medicine.

DNA repair pathways and their therapeutic potential in lung cancer

Benjamin Solomon, Derek J. Richard, K. O'Byrne, 2014 .

Comprehensive genomic profiles of small cell lung cancer

Martin Vingron, Jan O. Korbel, Lucia Anna Muscarella, 2015, Nature.

Safety and efficacy of lorlatinib (PF-06463922) from the dose-escalation component of a study in patients with advanced ALK+ or ROS1+ non-small cell lung cancer (NSCLC).

Benjamin Solomon, A. Shaw, E. Felip, 2016 .

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology

Benjamin Solomon, Neal I. Lindeman, Dara L. Aisner, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.